References
- Jamei M , MarciniakS, FengK, BarnettA, TuckerG, Rostami-HodjeganA. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol.5 (2), 211–223 (2009).
- Kuentz M , NickS, ParrottN, RöthlisbergerD. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. Eur. J. Pharm. Sci.27 (1), 91–99 (2006).
- Wagner JG . History of pharmacokinetics. Pharmacol. Ther.12 (3), 537–562 (1981).
- Clark B , SmithDA. Pharmacokinetics and toxicity testing. Crit. Rev. Toxicol.12 (4), 343–385 (1984).
- Henion JD , MaylinGA. Drug analysis by direct liquid introduction micro liquid chromatography mass spectrometry. Biomed. Mass Spectrom.7 (3), 115–121 (1980).
- Rowland M , BenetLZ, GrahamGG. Clearance concepts in pharmacokinetics. J. Pharmacokinet Biopharm.1 (2), 123–136 (1973).
- Houston JB . Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol.47 (9), 1469–1479 (1994).
- Smith DA . Evolution of ADME science: where else can modeling and simulation contribute?Mol. Pharm.10 (4), 1162–1170 (2013).
- Ballard P , BrassilP, BuiKHet al.. The right compound in the right assay at the right time: an integrated discovery DMPK strategy. Drug Metab. Rev.44 (3), 224–252 (2012).
- Riley RJ , McGinnityDF, AustinRP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos.33 (9), 1304–1311 (2005).
- Peck CC . Quantitative clinical pharmacology is transforming drug regulation. J. Pharmacokinet Pharmacodyn.37 (6), 617–628 (2010).
- Gessel MM , NorrisJL, CaprioliRM. MALDI imaging mass spectrometry: spatial molecular analysis to enable a new age of discovery. J. Proteomics107C, 71–82 (2014).
- Ellis SR , BruinenAL, HeerenRM. A critical evaluation of the current state-of-the-art in quantitative imaging mass spectrometry. Anal. Bioanal. Chem.406 (5), 1275–1289 (2014).